Skip to main content
. 2014 May 7;57(11):4569–4583. doi: 10.1021/jm500569h

Figure 5.

Figure 5

Assessment of estrogenic/antiestrogenic properties of the test compounds on inducing estrogen-responsive gene’s mRNA expression in MCF-7:WS8 breast cancer cell line: (A) pS2 gene; (B) GREB1 gene; (C) PgR gene. Treatment with E2 was made at 10–10 M. All of the other test compounds were treated at 10–6 M. The fold change of the mRNA was first calculated using the ΔΔCt method. Corresponding 10–10 M E2 control values were considered as 100%, and all other treatments were calculated accordingly.